GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » Cyclically Adjusted Revenue per Share

Duopharma Biotech Bhd (XKLS:7148) Cyclically Adjusted Revenue per Share : RM0.68 (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Duopharma Biotech Bhd's adjusted revenue per share for the three months ended in Sep. 2023 was RM0.176. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is RM0.68 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Duopharma Biotech Bhd's average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-27), Duopharma Biotech Bhd's current stock price is RM1.18. Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was RM0.68. Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio of today is 1.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Duopharma Biotech Bhd was 4.27. The lowest was 1.66. And the median was 2.31.


Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Chart

Duopharma Biotech Bhd Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.55 0.63

Duopharma Biotech Bhd Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.63 0.65 0.67 0.68

Competitive Comparison of Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio falls into.



Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Duopharma Biotech Bhd's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.176/129.8595*129.8595
=0.176

Current CPI (Sep. 2023) = 129.8595.

Duopharma Biotech Bhd Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.079 98.326 0.104
201403 0.070 99.695 0.091
201406 0.094 100.560 0.121
201409 0.104 100.428 0.134
201412 0.088 99.070 0.115
201503 0.105 99.621 0.137
201506 0.130 100.684 0.168
201509 0.091 100.392 0.118
201512 0.102 99.792 0.133
201603 0.092 100.470 0.119
201606 0.091 101.688 0.116
201609 0.092 101.861 0.117
201612 0.085 101.863 0.108
201703 0.139 102.862 0.175
201706 0.315 103.349 0.396
201709 0.133 104.136 0.166
201712 0.129 104.011 0.161
201803 0.154 105.290 0.190
201806 0.143 106.317 0.175
201809 0.143 106.507 0.174
201812 0.131 105.998 0.160
201903 0.171 107.251 0.207
201906 0.162 108.070 0.195
201909 0.159 108.329 0.191
201912 0.151 108.420 0.181
202003 0.174 108.902 0.207
202006 0.157 108.767 0.187
202009 0.144 109.815 0.170
202012 0.142 109.897 0.168
202103 0.180 111.754 0.209
202106 0.165 114.631 0.187
202109 0.182 115.734 0.204
202112 0.163 117.630 0.180
202203 0.195 121.301 0.209
202206 0.192 125.017 0.199
202209 0.186 125.227 0.193
202212 0.160 125.222 0.166
202303 0.211 127.348 0.215
202306 0.175 128.729 0.177
202309 0.176 129.860 0.176

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Duopharma Biotech Bhd  (XKLS:7148) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.18/0.68
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Duopharma Biotech Bhd was 4.27. The lowest was 1.66. And the median was 2.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd (XKLS:7148) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines